Proceeds to Support Commercial Ramp & New Product Development of the Saber® Technology Platform MONTEREY, Calif.–(BUSINESS WIRE)–Elevation Spine, Inc., the leading innovator of integrated-fixation spinal technologies, today announced the completion of its Series B Preferred Stock financing, totaling $11 million. The funding was led by Technology Venture Partners (“TVP”) and included participation from Mutual Capital … [Read more…]
ITHACA, N.Y.–(BUSINESS WIRE)–Rheonix Inc. announced today that the United States Food and Drug Administration (FDA) has issued an expanded Emergency Use Authorization (EUA) for the Rheonix COVID-19™ MDx Assay to include home collection using the Rheonix Laboratories COVID-19 PCR Test Saliva Home Collection Kit. Rheonix’s fully automated sample-to-answer COVID-19 assay received its initial EUA for … [Read more…]
Goal To Fully Align with Self-Insured Employers & Dramatically Reduce Costs No Hidden Fees or Rebates PALO ALTO, Calif.–(BUSINESS WIRE)–#behavioralhealth–Transcarent, a new, different, and better health and care experience company for employees of self-insured employers and their families, today announced the launch of the industry’s first fully transparent and integrated pharmacy benefit offering designed to … [Read more…]
BOSTON–(BUSINESS WIRE)–Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The study is an update to a 2020 interim analysis and was presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference taking place in Boston. … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Rare Disease Genetic Testing Market Size, Share & Trends Analysis Report by Disease Type (Neurological, CVDs), by Specialty (Molecular, Biochemical), by Technology (NGS, PCR-based), by End Use, and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering. The global rare disease genetic testing market size is expected to reach USD 2.52 billion … [Read more…]
OTTAWA, Ontario–(BUSINESS WIRE)–Operation Lifesaver (OL) Canada today unveiled four new #STOPTrackTragedies videos to mark the beginning of Rail Safety Week (September 19-25, 2022) and to remind Canadians that taking risks near tracks and trains could cost them a limb, or their life. Every year, 2,100 North Americans are seriously injured or killed when they engage … [Read more…]
– 12-Year Agreement Prioritizes Environmental Stewardship to Help Create Clean Energy Solutions and Advances Progress Towards Net-Zero Greenhouse Gas (GHG) Emissions Targets – Agreement Expected to Create Up To 350,000 Megawatt Hours (MWh) of Renewable Energy Credits per Year, Accounting for Approximately 20 Percent of Takeda’s Current Enterprise Scope 1 and 2 Greenhouse Gas (GHG) … [Read more…]
Customers can now benefit from specialized software designed to increase the profitability of Medicare Advantage risk contracts SAN DIEGO–(BUSINESS WIRE)–ForeSee Medical today announced it has launched The ForeSee App on Salesforce AppExchange, empowering customers to increase the profitability of Medicare Advantage risk contracts. The ForeSee App assists Salesforce Health Cloud users RAF scores and improves … [Read more…]
BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is convening its annual digital health user conference, Management Expert Exchange in Transplantation (MEET), September 18-20 in Las Vegas, Nevada. The CareDx … [Read more…]
CHMP recommends approval of BRUKINSA for the treatment of relapsed or refractory marginal zone lymphoma If approved, BRUKINSA will be the first and only approved Bruton’s Tyrosine Kinase (BTK) inhibitor for marginal zone lymphoma in Europe CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused … [Read more…]
